Amvuttra to treat polyneuropathy of amyloidosis
Drug Name: Amvuttra Active Ingredient: vutrisiran Indications: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis Approval Date: 6/13/2022 Company: Alnylam Pharmaceuticals, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf